Why the study?
It was unknown whether whole blood BDNF, which reflects the total blood BDNF pool and minimizes platelet aggregation confounds, can serve as a biomarker for MDD or predict antidepressant treatment response.
Does escitalopram alter whole blood BDNF levels in patients with MDD and healthy controls?
Does escitalopram alter whole blood BDNF levels in patients with MDD and healthy controls?
Answers are grounded in this paper and cite their sources.
Whole blood BDNF is reduced in MDD compared to healthy controls but does not change with escitalopram treatment, suggesting it may serve as a diagnostic but not prognostic biomarker.
Brain-derived neurotrophic factor (BDNF) plays a key role in neuroplasticity and has been implicated in both the pathophysiology of Major Depressive Disorder (MDD) and treatment effects. Unlike serum BDNF (s-BDNF), which largely reflects platelet-derived BDNF released during coagulation, whole blood BDNF (wb-BDNF) measures the total blood BDNF pool, minimizing confounds related to platelet aggregation. This study aims to assess whether wb-BDNF levels can serve as a biomarker for MDD and/or as a predictor of antidepressant treatment response. We measured wb-BDNF before and after 4–12 weeks of escitalopram intervention in two studies: a non-randomized, single-arm clinical trial of 97 unmedicated patients with MDD and a randomized, double-blind, placebo-controlled trial with 66 healthy controls (HC). The BDNF Val65Met polymorphism was also determined. Unmedicated patients with MDD had 14 % lower wb-BDNF than HC, but wb-BDNF prior to intervention was not associated with symptom severity, nor did it predict drug treatment outcome in the patients. Further, improvements in depression scores after 8 and 12 weeks of escitalopram was not associated with changes in wb-BDNF. In HC, wb-BDNF was similar in the placebo and escitalopram groups after 4 weeks of intervention. BDNF polymorphism was similar between HC and MDD, and responders and non-responders, and was not associated with wb-BDNF levels. wb-BDNF reflects the total blood BDNF pool and avoids platelet aggregation-related confounds seen in s-BDNF measures. wb-BDNF could be used as diagnosis but not as a prognosis biomarker, in MDD. Further research is needed to investigate changes in BDNF reservoirs and their implications. • Whole blood BDNF is reduced in MDD vs HC but shows no association with baseline depression severity in MDD patients. • Escitalopram intake does not change whole blood BDNF in patients with depression, nor in healthy controls. • Whole blood BDNF offers distinct insights into depression, complementing previous serum BDNF findings, by reflecting total blood BDNF independent of platelet aggregation effects.
No takes yet. Share an insight, caveat, or question.
Navarro et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: